How does the panel feel regarding the veracity of a class effect for
these agents especially in view of the HOPE findings and ramipril? Yusuf
and Gargs meta analysis in JAMA 1995 showed that all the ACE -I studied
had similar endpoints ( mortality and hospitalization). Has the evidence
changed or will any ACE-I protect my patients?
Paddy
--
Dr Paddy Quail
403 221 4370 (ph) 403 221 4371 (fax)
go.to/continuing.care
|